Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 2
2017 1
2018 1
2019 3
2020 1
2021 3
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean P. mollazadeh (52 results)?
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.
Lotan I, Chen JJ, Hacohen Y, Abdel-Mannan O, Mariotto S, Huda S, Gibbons E, Wilf-Yarkoni A, Hellmann MA, Stiebel-Kalish H, Pittock SJ, Flanagan EP, Molazadeh N, Anderson M, Salky R, Romanow G, Schindler P, Duchow AS, Paul F, Levy M. Lotan I, et al. Mult Scler. 2023 Aug;29(9):1080-1089. doi: 10.1177/13524585231184738. Epub 2023 Jul 10. Mult Scler. 2023. PMID: 37431144
A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation (p < 0.0001 for both outcome measures). CONCLUSION: IVIG may be an effective treatment option for acute MOGAD attacks. ...
A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation (p …
Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N, Akaishi T, Bose G, Nishiyama S, Chitnis T, Levy M. Molazadeh N, et al. Mult Scler Relat Disord. 2023 Dec;80:105093. doi: 10.1016/j.msard.2023.105093. Epub 2023 Oct 20. Mult Scler Relat Disord. 2023. PMID: 37949025
The same estimate was -0.08 (95%CI: -0.18, +0.02, p = 0.12) in MOGAD and +0.05 (95%CI: -0.05, +0.15, p = 0.35) in matched MS group. Comparing groups for the presence of CDW (i.e., PIRA) showed that PIRA is more associated with MS compared to AQP4+NMOSD (p = 0 …
The same estimate was -0.08 (95%CI: -0.18, +0.02, p = 0.12) in MOGAD and +0.05 (95%CI: -0.05, +0.15, p = 0.35) in matched MS g …
Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Molazadeh N, Bilodeau PA, Salky R, Bose G, Lotan I, Romanow G, Anderson MR, Matiello M, Chitnis T, Levy M. Molazadeh N, et al. J Neurol Sci. 2024 Mar 15;458:122909. doi: 10.1016/j.jns.2024.122909. Epub 2024 Jan 30. J Neurol Sci. 2024. PMID: 38335710

Starting maintenance therapy following the index event was associated with decreased risk of relapsing disease (HR:0.26; 95%CI: 0.12, 0.54; P < 0.001). Maintenance therapy with intravenous immunoglobulin (HR:0.1; 95% CI:0.01, 0.78, P = 0.02), rituximab (HR: 0.21;

…
Starting maintenance therapy following the index event was associated with decreased risk of relapsing disease (HR:0.26; 95%CI: 0.12, 0.54; …
Microvascular and structural analysis of the retina and choroid in heart failure patients with reduced ejection fraction.
Khalilipur E, Mahdizad Z, Molazadeh N, Faghihi H, Naderi N, Mehrabi Bahar M, Firouzi A, Sadeghipour P, Maleki M, Soltani Shahgoli S, Khalili Pour E, Riazi-Esfahani H. Khalilipur E, et al. Sci Rep. 2023 Apr 4;13(1):5467. doi: 10.1038/s41598-023-32751-w. Sci Rep. 2023. PMID: 37015968 Free PMC article.
We found no statistically significant differences in age-adjusted mean central macular thickness (CMT), superficial or deep retinal capillary plexus vascular densities, and choriocapillaris flow (CC flow) density between the HFrEF group and the normal controls, with the exception …
We found no statistically significant differences in age-adjusted mean central macular thickness (CMT), superficial or deep retinal capillar …
Glutamine supplementation can reduce some atherosclerosis markers after exhaustive exercise in young healthy males.
Alipanah-Moghadam R, Molazadeh L, Jafari-Suha Z, Naghizadeh-Baghi A, Mohajeri M, Nemati A. Alipanah-Moghadam R, et al. Nutrition. 2022 Feb;94:111506. doi: 10.1016/j.nut.2021.111506. Epub 2021 Oct 3. Nutrition. 2022. PMID: 34844156 Clinical Trial.

RESULTS: In the intervention group, the serum levels of leptin, cholesterol, and oxidized low-density lipoprotein were lower than in the control group after 2 wk of glutamine supplementation (P < 0.05). Interleukin-6 serum levels were lower in the intervention group com

…
RESULTS: In the intervention group, the serum levels of leptin, cholesterol, and oxidized low-density lipoprotein were lower than in the con …
Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS).
Ghajarzadeh M, Mirmosayyeb O, Molazadeh N, Sahraian MA, Bonavita S, Shaygannejad V. Ghajarzadeh M, et al. Int J Prev Med. 2022 Jul 15;13:102. doi: 10.4103/ijpvm.IJPVM_480_20. eCollection 2022. Int J Prev Med. 2022. PMID: 36119957 Free PMC article.
The patients with COVID-19 diagnosis were more frequently treated with rituximab (28% vs 24%, P = 0.001) than others, and cardiovascular comorbidity was more frequent in this group (8% vs 1.6%, P = 0.01). ...
The patients with COVID-19 diagnosis were more frequently treated with rituximab (28% vs 24%, P = 0.001) than others, and cardiovascu …
Prevalence and incidence of multiple sclerosis in Ardabil, Northwest of Iran.
Molazadeh N, Mohebi F, Altafi D, Sahraian MA. Molazadeh N, et al. Mult Scler Relat Disord. 2021 Jan;47:102605. doi: 10.1016/j.msard.2020.102605. Epub 2020 Oct 27. Mult Scler Relat Disord. 2021. PMID: 33217696
The F/M ratio was 2.92:1 and the mean onset age was 33.14 (95% CI: 31.56, 34.72) in 2018, significantly higher in males (P value= 0.01). CONCLUSION: Ardabil is a medium risk zone of MS. ...
The F/M ratio was 2.92:1 and the mean onset age was 33.14 (95% CI: 31.56, 34.72) in 2018, significantly higher in males (P value= 0.0 …
Is There a Correlation between Helicobacter Pylori and Enterohepatic Helicobacter Species and Gallstone Cholecystitis?
Fatemi SM, Doosti A, Shokri D, Ghorbani-Dalini S, Molazadeh M, Tavakoli H, Minakari M, Tavakkoli H. Fatemi SM, et al. Middle East J Dig Dis. 2018 Jan;10(1):24-30. doi: 10.15171/mejdd.2017.86. Epub 2018 Jan 8. Middle East J Dig Dis. 2018. PMID: 29682244 Free PMC article.
Moreover, there was an association between H. pylori and acute cholecystitis (p = 0.048), which was found to be stronger in 31-40-year-olds group (p = 0.003). ...
Moreover, there was an association between H. pylori and acute cholecystitis (p = 0.048), which was found to be stronger in 31-40-yea …
Comparison of the Effects of Govarcin Herbal Capsule and Metoclopramide for Alleviating Gastrointestinal Symptoms in Patients with Functional Dyspepsia: A Randomized Double-blind Clinical Trial.
Asghari M, Ahmadpour S, Molazadeh M, Jafari MM, Hormati A, Pashaei MR, Mohammadpour Y, Habibi MA, Mohammadbeigi A, Hoseini SME. Asghari M, et al. Rev Recent Clin Trials. 2023 Dec 1. doi: 10.2174/0115748871266848231120112355. Online ahead of print. Rev Recent Clin Trials. 2023. PMID: 38099534 Clinical Trial.
RESULTS: Clinical symptom score changes between Govarcin and Metoclopramide patients' groups showed that there was no significant difference in any of the clinical symptom scores (except for heartburn, p-vale=0.012) between the study groups. Nepean score in Govarcin group …
RESULTS: Clinical symptom score changes between Govarcin and Metoclopramide patients' groups showed that there was no significant difference …
Pediatric multiple sclerosis and its familial recurrence: A population based study (1999-2017).
Eskandarieh S, Sahraiain MA, Molazadeh N, Moghadasi AN. Eskandarieh S, et al. Mult Scler Relat Disord. 2019 Nov;36:101377. doi: 10.1016/j.msard.2019.101377. Epub 2019 Aug 27. Mult Scler Relat Disord. 2019. PMID: 31473489
The female to male ratio was 2.02:1 in pre-pubertal cases (3-12 y/o), but it increased to 3.69:1 in 13-18 y/o age groups (P value = 0.001, OR = 1.82; 95% CI = 1.27-2.26). There were 288 (14.9%) cases with positive familial history of MS. The strongest association between M …
The female to male ratio was 2.02:1 in pre-pubertal cases (3-12 y/o), but it increased to 3.69:1 in 13-18 y/o age groups (P value = 0 …
18 results